Gut resistome of NSCLC patients treated with immunotherapy

BackgroundThe newest method of treatment for patients with NSCLC (non-small cell lung cancer) is immunotherapy directed at the immune checkpoints PD-1 (Programmed Cell Death 1) and PD-L1 (Programmed Cell Death Ligand 1). PD-L1 is the only validated predictor factor for immunotherapy efficacy, but it...

Full description

Bibliographic Details
Published in:Frontiers in Genetics
Main Authors: Ewelina Iwan, Anna Grenda, Arkadiusz Bomba, Katarzyna Bielińska, Dariusz Wasyl, Robert Kieszko, Anna Rolska-Kopińska, Izabela Chmielewska, Paweł Krawczyk, Kamila Rybczyńska-Tkaczyk, Małgorzata Olejnik, Janusz Milanowski
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-08-01
Subjects:
resistome
microbiome
NSCLC
immunotherapy
metagenomics
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2024.1378900/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2024.1378900/full

Similar Items